Published in Proc Natl Acad Sci U S A on March 03, 2004
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J (2004) 5.67
Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol (2004) 4.76
Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog (2009) 4.24
HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology (2008) 3.72
Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol (2006) 3.63
APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res (2006) 3.15
Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol (2009) 2.95
Intrinsic antiviral immunity. Nat Immunol (2012) 2.71
Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol (2007) 2.64
Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol (2006) 2.63
Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res (2005) 2.43
Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med (2010) 2.43
Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci U S A (2005) 2.42
Host restriction factors blocking retroviral replication. Annu Rev Genet (2008) 2.41
APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2009) 2.40
Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol (2004) 2.34
Going wild: lessons from naturally occurring T-lymphotropic lentiviruses. Clin Microbiol Rev (2006) 2.28
Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. J Virol (2005) 2.20
Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J Virol (2007) 2.17
Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol (2006) 2.16
Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J Virol (2005) 2.04
The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc Natl Acad Sci U S A (2005) 1.95
Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. J Virol (2005) 1.84
RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog (2009) 1.84
All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Res (2007) 1.79
A macaque model of HIV-1 infection. Proc Natl Acad Sci U S A (2009) 1.76
Loss of Siglec expression on T lymphocytes during human evolution. Proc Natl Acad Sci U S A (2006) 1.75
Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J Virol (2006) 1.69
Functions, structure, and read-through alternative splicing of feline APOBEC3 genes. Genome Biol (2008) 1.63
Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses. J Virol (2010) 1.61
Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J Virol (2008) 1.59
Antiretroviral activity and Vif sensitivity of rhesus macaque APOBEC3 proteins. J Virol (2007) 1.56
Plunder and stowaways: incorporation of cellular proteins by enveloped viruses. J Virol (2005) 1.56
Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology (2004) 1.56
Two-stepping through time: mammals and viruses. Trends Microbiol (2011) 1.54
Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J Virol (2007) 1.53
Restriction of foamy viruses by APOBEC cytidine deaminases. J Virol (2006) 1.52
Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol (2007) 1.51
Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res (2006) 1.46
Further investigation of simian immunodeficiency virus Vif function in human cells. J Virol (2004) 1.46
Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog (2010) 1.43
Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol (2013) 1.39
A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J Virol (2009) 1.38
Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J Virol (2008) 1.37
The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. Nat Struct Mol Biol (2012) 1.36
A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J Virol (2009) 1.36
Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity. J Virol (2010) 1.35
The range of human APOBEC3H sensitivity to lentiviral Vif proteins. J Virol (2010) 1.34
APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology (2009) 1.27
Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells. J Virol (2009) 1.26
The host restriction factor APOBEC3G and retroviral Vif protein coevolve due to ongoing genetic conflict. Cell Host Microbe (2012) 1.26
A challenge to the ancient origin of SIVagm based on African green monkey mitochondrial genomes. PLoS Pathog (2007) 1.25
Model structure of human APOBEC3G. PLoS One (2007) 1.24
Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends Pharmacol Sci (2009) 1.24
Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J Virol (2008) 1.24
Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS One (2008) 1.23
Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog (2007) 1.22
Analysis of the Macaca mulatta transcriptome and the sequence divergence between Macaca and human. Genome Biol (2005) 1.20
Feline lentivirus evolution in cross-species infection reveals extensive G-to-A mutation and selection on key residues in the viral polymerase. J Virol (2006) 1.20
Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc Natl Acad Sci U S A (2006) 1.20
Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J Virol (2010) 1.20
Convergence and divergence in the evolution of the APOBEC3G-Vif interaction reveal ancient origins of simian immunodeficiency viruses. PLoS Pathog (2013) 1.19
Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo. J Virol (2011) 1.18
The AKV murine leukemia virus is restricted and hypermutated by mouse APOBEC3. J Virol (2009) 1.17
The betaretrovirus Mason-Pfizer monkey virus selectively excludes simian APOBEC3G from virion particles. J Virol (2006) 1.17
A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J Biol Chem (2010) 1.17
Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism. J Virol (2008) 1.15
HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain. Proc Natl Acad Sci U S A (2009) 1.06
Host restriction factors in retroviral infection: promises in virus-host interaction. Retrovirology (2012) 1.05
FIV cross-species transmission: an evolutionary prospective. Vet Immunol Immunopathol (2008) 1.05
A New World primate deficient in tetherin-mediated restriction of human immunodeficiency virus type 1. J Virol (2009) 1.05
Modeling infectious disease in mice: co-adaptation and the role of host-specific IFNgamma responses. PLoS Pathog (2009) 1.04
The breadth of antiviral activity of Apobec3DE in chimpanzees has been driven by positive selection. J Virol (2011) 1.04
Functional domain organization of human APOBEC3G. Virology (2008) 1.03
HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol Aspects Med (2010) 1.03
HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Virology (2007) 1.03
Advances in the structural understanding of Vif proteins. Curr HIV Res (2008) 1.03
Inhibition of alpharetrovirus replication by a range of human APOBEC3 proteins. J Virol (2007) 1.03
Structural Features of Antiviral APOBEC3 Proteins are Linked to Their Functional Activities. Front Microbiol (2011) 1.02
APOBEC3G: an intracellular centurion. Philos Trans R Soc Lond B Biol Sci (2009) 1.02
Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection. PLoS One (2008) 1.01
Antiviral Mechanism and Biochemical Basis of the Human APOBEC3 Family. Front Microbiol (2012) 1.00
Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. Front Microbiol (2014) 1.00
Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. PLoS Genet (2014) 1.00
Productive replication of Vif-chimeric HIV-1 in feline cells. J Virol (2010) 0.99
Retroelements versus APOBEC3 family members: No great escape from the magnificent seven. Front Microbiol (2012) 0.99
Structure of the Vif-binding domain of the antiviral enzyme APOBEC3G. Nat Struct Mol Biol (2015) 0.99
Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis. Nucleic Acids Res (2009) 0.98
APOBEC3G polymorphism as a selective barrier to cross-species transmission and emergence of pathogenic SIV and AIDS in a primate host. PLoS Pathog (2013) 0.98
Vif of feline immunodeficiency virus from domestic cats protects against APOBEC3 restriction factors from many felids. J Virol (2010) 0.97
Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases. Cell Microbiol (2008) 0.97
Antiretroviral activity of ancestral TRIM5alpha. J Virol (2007) 0.97
APOBEC3G: a double agent in defense. Trends Biochem Sci (2011) 0.96
Stem cell-based anti-HIV gene therapy. Virology (2011) 0.94
HIV and SIV infection: the role of cellular restriction and immune responses in viral replication and pathogenesis. APMIS (2009) 0.94
Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif. J Mol Biol (2011) 0.93
Insights into cellular factors that regulate HIV-1 replication in human cells. Biochemistry (2011) 0.92
Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells. J Virol (2007) 0.91
Uracil within DNA: an actor of antiviral immunity. Retrovirology (2008) 0.89
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 13.24
DNA deamination mediates innate immunity to retroviral infection. Cell (2003) 12.10
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science (2003) 10.79
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell (2003) 9.48
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med (2003) 9.22
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med (2003) 8.40
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell (2003) 7.42
The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med (2003) 5.97
The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol (2003) 5.58
Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem (2003) 5.45
A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc Natl Acad Sci U S A (2002) 4.52
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol (2003) 4.23
The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol (1996) 3.22
Identification of highly attenuated mutants of simian immunodeficiency virus. J Virol (1998) 2.94
Subcellular localization of the Vif protein of human immunodeficiency virus type 1. J Virol (1994) 2.35
Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol (1995) 2.35
Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol (1996) 2.35
Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. J Virol (2001) 1.58
Functional differences between human and bovine immunodeficiency virus Tat transcription factors. J Virol (2000) 1.07
Simian immunodeficiency viruses of diverse origin can use CXCR4 as a coreceptor for entry into human cells. J Virol (2000) 1.02
Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev (2003) 17.64
Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA (2004) 11.52
Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell (2002) 10.30
MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A (2003) 8.73
Sequence requirements for micro RNA processing and function in human cells. RNA (2003) 7.46
Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc Natl Acad Sci U S A (2005) 5.88
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J (2004) 5.67
MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. Nature (2008) 5.29
A viral microRNA functions as an orthologue of cellular miR-155. Nature (2007) 5.09
Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog (2006) 4.80
Recognition and cleavage of primary microRNA precursors by the nuclear processing enzyme Drosha. EMBO J (2004) 4.54
Structural requirements for pre-microRNA binding and nuclear export by Exportin 5. Nucleic Acids Res (2004) 3.81
Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc Natl Acad Sci U S A (2006) 3.76
Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol (2002) 3.42
Viruses, microRNAs, and host interactions. Annu Rev Microbiol (2010) 3.30
The role of RNAi and microRNAs in animal virus replication and antiviral immunity. Genes Dev (2009) 3.30
APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res (2006) 3.15
Viral and cellular microRNAs as determinants of viral pathogenesis and immunity. Cell Host Microbe (2008) 3.14
The imprinted H19 noncoding RNA is a primary microRNA precursor. RNA (2007) 2.91
Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology (2005) 2.84
Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and MicroRNA biogenesis. J Virol (2004) 2.77
Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology (2004) 2.75
A novel assay for viral microRNA function identifies a single nucleotide polymorphism that affects Drosha processing. J Virol (2006) 2.71
Efficient processing of primary microRNA hairpins by Drosha requires flanking nonstructured RNA sequences. J Biol Chem (2005) 2.60
Exon junction complexes mediate the enhancing effect of splicing on mRNA expression. Proc Natl Acad Sci U S A (2003) 2.52
The viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS Pathog (2012) 2.45
Analysis of the stimulatory effect of splicing on mRNA production and utilization in mammalian cells. RNA (2003) 2.40
Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. RNA (2004) 2.21
Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases. Curr Biol (2005) 2.21
Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. J Virol (2005) 2.20
RNA interference in human cells is restricted to the cytoplasm. RNA (2002) 2.16
Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines. Cell Host Microbe (2011) 2.13
A mammalian herpesvirus uses noncanonical expression and processing mechanisms to generate viral MicroRNAs. Mol Cell (2010) 2.10
MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. EMBO J (2013) 2.01
Analysis of the interaction of primate retroviruses with the human RNA interference machinery. J Virol (2007) 1.93
In-depth analysis of Kaposi's sarcoma-associated herpesvirus microRNA expression provides insights into the mammalian microRNA-processing machinery. J Virol (2009) 1.90
Formation of Tap/NXT1 heterodimers activates Tap-dependent nuclear mRNA export by enhancing recruitment to nuclear pore complexes. Mol Cell Biol (2002) 1.86
Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. J Virol (2005) 1.84
Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol (2010) 1.83
Transcriptional origin of Kaposi's sarcoma-associated herpesvirus microRNAs. J Virol (2006) 1.77
Selective inhibition of Alu retrotransposition by APOBEC3G. Gene (2006) 1.75
Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol (2003) 1.73
Use of RNA polymerase II to transcribe artificial microRNAs. Methods Enzymol (2005) 1.68
A human herpesvirus microRNA inhibits p21 expression and attenuates p21-mediated cell cycle arrest. J Virol (2010) 1.64
Analysis of human alphaherpesvirus microRNA expression in latently infected human trigeminal ganglia. J Virol (2009) 1.63
Identification of microRNAs expressed in two mosquito vectors, Aedes albopictus and Culex quinquefasciatus. BMC Genomics (2010) 1.59
Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int (2003) 1.52
A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus. PLoS Pathog (2011) 1.51
Cloning and analysis of microRNAs encoded by the primate gamma-herpesvirus rhesus monkey rhadinovirus. Virology (2007) 1.40
Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS One (2011) 1.34
The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology (2007) 1.33
Influenza A virus expresses high levels of an unusual class of small viral leader RNAs in infected cells. MBio (2010) 1.27
Human papillomavirus genotype 31 does not express detectable microRNA levels during latent or productive virus replication. J Virol (2006) 1.27
Both ran and importins have the ability to function as nuclear mRNA export factors. RNA (2002) 1.27
Identification of viral microRNAs expressed in human sacral ganglia latently infected with herpes simplex virus 2. J Virol (2009) 1.21
Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. RNA (2008) 1.19
Mutational inactivation of herpes simplex virus 1 microRNAs identifies viral mRNA targets and reveals phenotypic effects in culture. J Virol (2013) 1.19
In-depth analysis of the interaction of HIV-1 with cellular microRNA biogenesis and effector mechanisms. MBio (2013) 1.18
The betaretrovirus Mason-Pfizer monkey virus selectively excludes simian APOBEC3G from virion particles. J Virol (2006) 1.17
RNAi the natural way. Nat Genet (2005) 1.15
Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism. J Virol (2008) 1.15
Recognition and cleavage of primary microRNA transcripts. Methods Mol Biol (2006) 1.11
The members of an Epstein-Barr virus microRNA cluster cooperate to transform B lymphocytes. J Virol (2011) 1.10
Human APOBEC3 proteins can inhibit xenotropic murine leukemia virus-related virus infectivity. Virology (2010) 1.09
Differential RISC association of endogenous human microRNAs predicts their inhibitory potential. Nucleic Acids Res (2014) 1.09
MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference. PLoS Pathog (2010) 1.04
Functional domain organization of human APOBEC3G. Virology (2008) 1.03
Recruitment of the Crm1 nuclear export factor is sufficient to induce cytoplasmic expression of incompletely spliced human immunodeficiency virus mRNAs. J Virol (2002) 1.03
Inhibition of alpharetrovirus replication by a range of human APOBEC3 proteins. J Virol (2007) 1.03
Identification of novel, highly expressed retroviral microRNAs in cells infected by bovine foamy virus. J Virol (2014) 1.00
Analysis of rhesus rhadinovirus microRNAs expressed in virus-induced tumors from infected rhesus macaques. Virology (2010) 1.00
Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors. J Gene Med (2005) 0.98
MicroRNA target site identification by integrating sequence and binding information. Nat Methods (2013) 0.96
The crystal structure and mutational analysis of a novel RNA-binding domain found in the human Tap nuclear mRNA export factor. Proc Natl Acad Sci U S A (2002) 0.94
Requirement of the human T-cell leukemia virus (HTLV-1) tax-stimulated HIAP-1 gene for the survival of transformed lymphocytes. Blood (2006) 0.94
Evolutionary conservation of primate lymphocryptovirus microRNA targets. J Virol (2013) 0.91
Protocols for expression and functional analysis of viral microRNAs. Methods Enzymol (2007) 0.88
Human immunodeficiency virus: nuclear RNA export unwound. Nature (2005) 0.87
A cluster of virus-encoded microRNAs accelerates acute systemic Epstein-Barr virus infection but does not significantly enhance virus-induced oncogenesis in vivo. J Virol (2013) 0.87
Cyclophilin B escorts the hepatitis C virus RNA polymerase: a viral achilles heel? Mol Cell (2005) 0.83
Persistently adenovirus-infected lymphoid cells express microRNAs derived from the viral VAI and especially VAII RNA. Virology (2013) 0.81
In vivo hypermutation of xenotropic murine leukemia virus-related virus DNA in peripheral blood mononuclear cells of rhesus macaque by APOBEC3 proteins. Virology (2011) 0.81
siRNAs: a new wave of RNA-based therapeutics. J Antimicrob Chemother (2003) 0.81
Human topoisomerase I promotes HIV-1 proviral DNA synthesis: implications for the species specificity and cellular tropism of HIV-1 infection. Proc Natl Acad Sci U S A (2003) 0.80
Analysis of the mRNA targetome of microRNAs expressed by Marek's disease virus. MBio (2014) 0.79
HIV-1 infection: fooling the gatekeeper. Nat Med (2003) 0.79
Two new monoclonal antibodies for biochemical and flow cytometric analyses of human interferon regulatory factor-3 activation, turnover, and depletion. Methods (2012) 0.77
Nonsense mediated decay induced by tethered human UPF3B is restricted to the cytoplasm. RNA Biol (2004) 0.76